Patents Issued in September 1, 2015
  • Razor comprising a molded shaving aid composition comprising a pyrithione source
    Patent number: 9119796
    Abstract: Razors comprising a shaving aid comprising a soap base and a pyrithione source.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: September 1, 2015
    Assignee: The Gillette Company
    Inventors: Jason Edward Cook, Chunpeng Jiang, Brian Joseph Limberg, Edward Dewey Smith, III, Juan Wang, Xiaoyong Wang
  • Combination of a light ray with a cytochrome C oxidase substrate particularly for improving the appearance of the skin and/or hair
    Patent number: 9119798
    Abstract: The invention relates to the combination of a light ray with a cytochrome C oxidase substrate for improving the appearance of the skin and/or the hair.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: September 1, 2015
    Assignee: L'OREAL
    Inventors: Julien Laboureau, Quang Lan Nguyen, Dang-Man Pham
  • Transdermal compositions comprising an active agent layer and an active agent conversion layer
    Patent number: 9119799
    Abstract: Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: September 1, 2015
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard Hamlin, Jianye Wen
  • HIG2 and URLC10 epitope peptide and vaccines containing the same
    Patent number: 9119800
    Abstract: The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: September 1, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
  • Cancer vaccine composition
    Patent number: 9119801
    Abstract: A cancer vaccine composition for human leukocyte antigen (HLA)-A*0206-positive persons, comprising a protein product of the tumor suppressor gene WT1 or a partial peptide thereof.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: September 1, 2015
    Assignee: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
    Inventor: Haruo Sugiyama
  • LpfA antigen for prevention and treatment of infectious diseases
    Patent number: 9119802
    Abstract: The present disclosure relates to methods and compositions for the treatment and prevention of microbial infections and for the enhancement of resistance to infection. The disclosure includes administration of an effective amount of an E. coli LpfA antigen to enhance the immune system to prevent infections that cause, e.g., inflammatory bowel diseases, bovine mastitis and metritis. The disclosure also includes methods for diagnosing microbial infection and conditions associated with microbial infection by detecting an E. coli LpfA polypeptide or nucleic acid.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: September 1, 2015
    Assignee: Cornell University
    Inventors: Kenneth W. Simpson, Belgin Dogan
  • Carious tooth vaccine and preparation method
    Patent number: 9119803
    Abstract: The present invention provides a vaccine composition for dental caries caused by S. mutans infection, where the vaccine composition comprises an antigen derived from a surface protein PAc of S. mutans and an adjuvant derived from flagellin. The present invention further provides methods for preparing the vaccine composition. The present invention also provides methods for preventing or curing dental caries caused by S. mutans by administrating to a subject the vaccine composition.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: September 1, 2015
    Assignee: Wuhan Institute of Virology, Chinese Academy of Sciences
    Inventors: Huimin Yan, Wei Shi, Ying Sun, Jingyi Yang
  • Live attenuated strains as a single dose vaccine against whooping cough
    Patent number: 9119804
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: September 1, 2015
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et da la Recherche Medicale
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Therapy and prevention of problem drinking
    Patent number: 9119805
    Abstract: The present invention provides methods for the therapy and prevention of problem drinking in alcohol-dependent and non-dependent subjects and those at risk of developing problem drinking behavior, and compositions of matter comprising oxytocin or an analog or derivative thereof or an agonist or partial agonist of an oxytocin receptor that are useful in preventing or treating problem drinking.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: September 1, 2015
    Assignee: THE UNIVERSITY OF SYDNEY
    Inventors: Iain Stewart McGregor, Dean Samuel Carson, Adam John Guastella, Michael Thomas Bowen
  • Culturing circular ssDNA viruses for the production of vaccines
    Patent number: 9119806
    Abstract: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by addition of interferons or agents which ensure the production of endogenous interferons by said cell line and/or by the reduction of endosomal-lysosomal system acidification.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: September 1, 2015
    Inventors: Hans Nauwynck, Gerald Misinzo, Sven Arnouts
  • Methods and materials for the generation of regulatory T cells
    Patent number: 9119807
    Abstract: Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25? T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: September 1, 2015
    Assignee: Life Technologies AS
    Inventors: Tanja Aarvak, Anne-Marie Rasmussen, Gunnar Kvalheim, Walter Gabriell Borelli Piedras, Anne Brunsvig
  • Treating neurodegenerative diseases with GGA or a derivative thereof
    Patent number: 9119808
    Abstract: Provided herein are methods for improving negative effects of ALS, AD, or ischemia, the methods comprising administering to a subject in need thereof a therapeutically effective amount of GGA, preferably present in the trans form, or a derivative thereof.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: September 1, 2015
    Assignee: Coyote Pharmaceuticals, Inc.
    Inventor: Hiroaki Serizawa
  • Compositions for treatment of attention deficit hyperactivity disorder
    Patent number: 9119809
    Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: September 1, 2015
    Assignee: Ironshore Pharmaceuticals & Development, Inc.
    Inventors: David Lickrish, Feng Zhang
  • Compositions and vaccines against influenza A and influenza B infections
    Patent number: 9119810
    Abstract: Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: September 1, 2015
    Assignees: Rutgers, The State University of New Jersey
    Inventors: Gaetano T. Montelione, Robert M. Krug, Yin Cuifeng, Ma Lichung
  • Fluorocarbon-linked peptide formulation
    Patent number: 9119811
    Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: September 1, 2015
    Assignee: Vaxin UK Limited
    Inventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 9119812
    Abstract: Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: September 1, 2015
    Assignee: MedImmune, LLC
    Inventors: Hong Jin, Xing Cheng, Kanta Subbarao
  • Vaccine against RSV
    Patent number: 9119813
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: September 1, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Katarina Radosevic, Jerome H. H. V. Custers, Jort Vellinga, Myra N. Widjojoatmodjo
  • Composition for prevention of influenza viral infection comprising sumac extract, air filter comprising the same and air cleaning device comprising the filter
    Patent number: 9119814
    Abstract: Disclosed are a composition for the prophylaxis of influenza viral infection comprising a sumac extract, an air filter coated with the same, and an air cleaner comprising the air filter. Having high inhibitory activity against influenza virus, the composition comprising a sumac extract can be applied to the prevention of influenza viral infection. Also, the filter coated with the composition can remove influenza viruses from the air so that it can be employed in an air cleaner for the prophylaxis of influenza viral infection.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: September 1, 2015
    Assignee: WOONGJIN COWAY CO., LTD.
    Inventors: Hyoung Joon Kim, Chan Jung Park
  • Combined measles-malaria vaccine
    Patent number: 9119815
    Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: September 1, 2015
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Reinhard Glueck, Agata Fazio, Viviana Giannino, Martin A Billeter
  • Method for prevention or treatment of diabetic angiogenesis impairment using C-peptide
    Patent number: 9119816
    Abstract: Disclosed are a method and composition for the prevention or treatment of diabetic angiogenesis impairment or diabetic wound-healing impairment, using C-peptide. Found to be able to induce angiogenesis through chemotactic migration of endothelial cells, cell migration to wounded areas, capillary-like network formation, and extracellular signal-regulated kinases 1/2 and Akt phosphorylation and nitric oxide production, C-peptide has prophylactic or therapeutic applications in a broad spectrum of various diabetic complications including diabetic angiogenesis impairment.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 1, 2015
    Assignee: AMOGREENTECH CO., LTD.
    Inventors: Kwon-Soo Ha, Young-Cheol Lim
  • Wild-type apolipoprotein L-I for use in the prevention of kidney diseases
    Patent number: 9119817
    Abstract: A wild-type human Apolipoprotein L-I is used in a method for the prevention and/or the treatment of renal disease.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: September 1, 2015
    Assignee: UNIVERSITE LIBRE DE BRUXELLES
    Inventor: Etienne Pays
  • Use of angiogenin or angiogenin agonists for treating diseases and disorders
    Patent number: 9119818
    Abstract: The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 1, 2015
    Assignees: AGRICULTURE VICTORIA SERVICES PTY LTD, Murray Goulburn Co-Operative Co., Limited
    Inventors: Matthew McDonagh, Benjamin Cocks, Angus Tester, Peter Hobman
  • Oral liquid compositions of rhein or diacerein
    Patent number: 9119819
    Abstract: The invention relates to liquid pharmaceutical compositions for oral administration comprising rhein or diacerein, or salts or esters or prodrugs thereof and processes for preparing such compositions.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: September 1, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Himanshu Verma, Rahul Dabre, Girish Kumar Jain
  • Tablet quickly disintegrating in the oral cavity and method for producing the same
    Patent number: 9119820
    Abstract: The present invention relates to a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient at a high content and a production method thereof. That is, the present invention provides a tablet which is rapidly disintegrated in an oral cavity containing an active ingredient in not less than 25% of the total weight, having a disintegration time of within 40 seconds and an absolute hardness of 1.8 N/mm2 or more, which is obtained by granulating a powder containing an active ingredient with a binding solution containing mannitol and corn-derived pregelatinized starch, mixing the resulting granules with at least one kind of a disintegrant selected from cornstarch, hydroxypropylstarch, carmellose and crospovidone, and compression molding the mixture.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: September 1, 2015
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Toru Fukushima, Takashi Shimizu, Teruko Yoshida
  • Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response
    Patent number: 9119821
    Abstract: Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: September 1, 2015
    Inventors: William Brusilow, Paolo Bernardi
  • Use of PDE7 inhibitors for the treatment of movement disorders
    Patent number: 9119822
    Abstract: A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: September 1, 2015
    Assignee: Omeros Corporation
    Inventors: John E. Bergmann, Neil S. Cutshall, Gregory A. Demopulos, Vincent A. Florio, George A. Gaitanaris, Patrick Gray, John Hohmann, Rene Onrust, Hongkui Zeng
  • Nitrite formulations and their use as nitric oxide prodrugs
    Patent number: 9119823
    Abstract: Compositions comprising from about 40 weight parts to about 1000 weight parts of a botanical nitrate source; from about 20 weight parts to about 500 weight parts of a botanical source of nitrite reduction activity; and from about 4 weight parts to about 100 weight parts of a nitrite salt. Use of said composition in methods of reducing triglycerides or reducing C-reactive protein levels are also provided.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 1, 2015
    Assignees: Board of Regents, The University of Texas System, Neogenis Labs, Inc.
    Inventors: Nathan S. Bryan, Janet Zand
  • Methods of use for IL-22 promoting rejuvenation of thymic and bone marrow function
    Patent number: 9119824
    Abstract: The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 1, 2015
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jarrod Dudakov, Marcel van den Brink, Alan Hanash
  • PKC-activating compounds for the treatment of neurodegenerative diseases
    Patent number: 9119825
    Abstract: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: September 1, 2015
    Assignee: Blanchette Rockefeller Neurosciences Institute
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
    Patent number: 9119826
    Abstract: The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: September 1, 2015
    Assignee: Pivotal Therapeutics, Inc.
    Inventors: George Jackowski, Rachelle MacSweeney, Nisar Shaikh, Jason Yantha, Valerie Schini-Kerth
  • Ophthalmic composition
    Patent number: 9119827
    Abstract: Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed oil, sunflower oil, purified lanolin and gel hydrocarbon.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: September 1, 2015
    Assignee: LION CORPORATION
    Inventors: Akito Odaka, Chieko Inoue, Manabu Hattori, Nobuhito Tabuchi
  • Antibodies with simultaneous subsite specificities to protein and lipid epitopes
    Patent number: 9119828
    Abstract: Antibodies and method of making antibodies, either monoclonal or polyclonal wherein said antibodies have dual or multi-specific binding capacity to more than one type of antigenic epitope. The antibodies have simultaneous or independent recognition subsites to each of the epitopes. Antigenic epitopes include lipids, peptides, proteins, amino acid sequences, sugars and carbohydrates. Monoclonal antibodies and a method of making monoclonal antibodies of the invention include monoclonal antibodies that are broadly neutralizing to HIV-1 or other envelop viruses wherein the monoclonal antibody has subsites that simultaneously recognize protein and lipid epitopes from the virus.
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: September 1, 2015
    Assignee: The United States of America as represented by The Secretary of the Army
    Inventor: Carl R. Alving
  • Methods and compositions for delivering interleukin-1 receptor antagonist
    Patent number: 9119829
    Abstract: Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: September 1, 2015
    Assignee: Biomet Biologics, LLC
    Inventors: Joel Higgins, Jacy Hoeppner, Jennifer Woodell-May
  • Use of PACAP for the treatment of viral infections in aquatic organisms
    Patent number: 9119830
    Abstract: The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: September 1, 2015
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Mario Pablo Estrada Garcia, Juna Maria Lugo Gonzalez, Yamila Carpio Gonzalez, Carolina Tafalla Piñeiro
  • Methods of manufacturing bioactive gels from extracellular matrix material
    Patent number: 9119831
    Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: September 1, 2015
    Assignee: ACell, Inc.
    Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
  • Methods of treating mild brain injury
    Patent number: 9119832
    Abstract: The present technology generally is directed to methods for treating mild brain injury and other neurological disorders in a subject. The methods can include administering to the subject an effective amount of a compound comprising ghrelin. The present technology is also generally directed to methods for treating mild brain injury and other neurological disorders in a subject, for example, by administering to the subject an effective amount of a compound comprising ghrelin modified to include octanoic acid or by limiting the carbon 14 content.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: September 1, 2015
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Vishal Bansal
  • Administration of relaxin to treat nephrogenic diseases of water imbalance involving aquaporin-4
    Patent number: 9119833
    Abstract: The present disclosure relates to methods of modulating aquaporin channels. Particularly, the disclosure provides methods of modulating aquaporin channels in a tissue of a mammal by administering relaxin.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 1, 2015
    Assignees: University of Melbourne, University of Florida Research Foundation, Inc.
    Inventors: Laura Parry, Kirk Conrad
  • Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof
    Patent number: 9119834
    Abstract: A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: September 1, 2015
    Assignee: University of Guelph
    Inventors: Éva Nagy, Bryan Griffin, Helena Grgic, Davor Ojkic
  • Methods and compositions for the sustained release of chromium
    Patent number: 9119835
    Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: September 1, 2015
    Assignee: JDS Therapeautics, LLC
    Inventor: James R. Komorowski
  • Use of amisulpride as an anti-emetic
    Patent number: 9119836
    Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 1, 2015
    Assignee: Acacia Pharma Limited
    Inventors: Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
  • Use of sEH inhibitors as analgesics
    Patent number: 9119837
    Abstract: The present invention provides methods and compositions for relieving pain and itching, of promoting wound healing, of reducing sickness behavior and of reducing inflammatory bowel disease or acne lesions in a subject by the topical administration of an inhibitor of soluble epoxide hydrolase, or of a cis-epoxyeicosatrienoic acid (“EET”), or by both.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: September 1, 2015
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Ahmet Bora Inceoglu
  • Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
    Patent number: 9119838
    Abstract: Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: September 1, 2015
    Assignee: N.V. NUTRICIA
    Inventors: Léon Mathieu Johannes Knippels, Elisabeth Catharina Adriana Maria Van Esch, Johan Garssen
  • Cancer treatment
    Patent number: 9119839
    Abstract: The present invention relates to methods of treating cancer, such as melanoma, by administering a CTLA4 antagonist to a subject with a serum C-Reactive Protein (CRP) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum CRP concentration in a subject, and then administering a CTLA4 antagonist if the CRP concentration is less than or equal to a certain amount. The invention further relates to, among other things, the use of serum CRP concentration as a predictive factor for a subject's response to a cancer treatment.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: September 1, 2015
    Assignee: Pfizer Inc.
    Inventors: Bo Huang, Margaret Ann Marshall
  • Use of an active substance binding to CD28 for producing a pharmaceutical composition for activating and expanding T cells
    Patent number: 9119840
    Abstract: The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the B-CLL.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: September 1, 2015
    Assignee: THERAMAB LLC
    Inventor: Thomas Hanke
  • Compositions and methods for preventing cardiac arrhythmia
    Patent number: 9119841
    Abstract: Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: September 1, 2015
    Assignee: CORMATRIX CARDIOVASCULAR, INC.
    Inventor: Robert G Matheny
  • Therapeutic meso-biliverdin IX? compositions and associated methods
    Patent number: 9119842
    Abstract: Methods and materials for treating various diseases and medical conditions with meso-biliverdin compositions. In addition methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin are provided.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: September 1, 2015
    Assignee: Utah State University
    Inventors: Jon Y. Takemoto, Dong Chen, Cheng-Wei T. Chang, Jonathan Wood
  • Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
    Patent number: 9119843
    Abstract: Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: September 1, 2015
    Assignee: Caliper Life Sciences, Inc.
    Inventors: Hao Chen, Ming Liu, Malathi Sathyamoorthy, Qi Su, Lisa Leary, Wayne Shaobin Zhong
  • Use of quaternary pyridinium salts as vasoprotective agents
    Patent number: 9119844
    Abstract: The invention relates to the use of quaternary pyridinium salts of formula (I), wherein R is NH2, CH3, or N(H)CH2OH group, and X is pharmaceutically acceptable counterion, for the preparation of vasoprotective agent for the treatment or prevention of conditions or diseases associated with dysfunction of vascular endothelium, oxidative stress, and/or insufficient production of endothelial prostacyclin PGI2, in particular but not exclusively if the above coincides with hypercholesterolemia, hypertriglyceridemia or low HDL level.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: September 1, 2015
    Assignee: PHARMENA SPOLKA AKCYJNA (PHARMENA S.A.)
    Inventors: Jerzy Gębicki, Stefan Chłopicki
  • Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
    Patent number: 9119845
    Abstract: Provided is a method of increasing the stability of wild-type ?-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of ?-glucocerebrosidase in the central nervous system would be beneficial. This method includes administering an effective amount of a pharmacologic chaperone for ?-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding ?-glucocerebrosidase. Further provided are ?-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of ?-glucocerebrosidase in vivo in the central nervous system.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: September 1, 2015
    Assignee: Amicus Therapeautics, Inc.
    Inventor: Brandon Alan Wustman
  • Method and composition for enhancing cognition in alzheimer's patients
    Patent number: 9119846
    Abstract: The invention relates to a pharmacologically active combination and a method of enhancing cognitive performance in a patient suffering from Alzheimer's disease comprising administering to said patient a cognitive performance-enhancing amount of melatonin or a melatonin agonist in a combination therapy with a nicotine receptor agonist.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: September 1, 2015
    Assignee: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Nava Zisapel, Moshe Laudon